Helen Torley

President and CEO, Halozyme Therapeutics

San Diego, California

About

Helen Torley, M.B. Ch.B., is the President and Chief Executive Officer of Halozyme Therapeutics, a biopharmaceutical company in San Diego, California that licenses its ENHANZE drug delivery technology to partners who want to give injected drugs under the skin. She has been CEO and a director since 2014. She trained as a physician and practised internal medicine and rheumatology.

Torley holds an M.B. Ch.B. from the University of Glasgow and is a Member of the Royal College of Physicians in Glasgow. She worked at Sandoz and Novartis from 1990 to 1997 in leadership positions, most recently as Vice President, Medical Affairs, and then at Bristol-Myers Squibb from 1997 to 2002 in sales and marketing leadership. From 2002 to 2011 she held several senior commercial positions at Amgen, and from 2011 to 2013 she was Chief Commercial Officer at Onyx Pharmaceuticals. Other biotech and pharmaceutical chief executives with pages on Whoo include Yvonne Greenstreet of Alnylam Pharmaceuticals and Kyle Gano of Neurocrine Biosciences.

Whoo compiled this page from public sources: Halozyme 2026 proxy statement (SEC), Halozyme Form 10-Q, September 2026 (SEC), Halozyme Form 10-K, 2025 (SEC). It is not affiliated with or endorsed by Helen Torley. Are you Helen Torley? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.

Want a page like this? Create yours from your résumé.

Experience

President and Chief Executive Officer — Halozyme Therapeutics


2014 – Present | San Diego, California

  • Director since 2014

Chief Commercial Officer — Onyx Pharmaceuticals


2011 – 2013

Senior commercial positions — Amgen


2002 – 2011

Sales and marketing leadership — Bristol-Myers Squibb


1997 – 2002

Leadership positions, most recently Vice President, Medical Affairs — Sandoz/Novartis


1990 – 1997

Education

MB ChB — University of Glasgow

MRCP — Royal College of Physicians, Glasgow

Projects